• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

ACOG Guidance on Thrombophilia in Pregnancy

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the inherited thrombophilias and differentiate between low and high risk thrombophilias
2. Apply the ACOG guidance when managing women at risk of VTE due to inherited thrombophilias

Estimated time to complete activity: 0.5 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from August 7 2018 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.4 contact hours.

Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:  

Pregnancy is a well-known hypercoagulable state and inherited thrombophilias can further increase the risk for maternal venous thromboembolism (VTE).  The ACOG recommendations (July 2018) address the different thrombophilias as well as associations with possible adverse pregnancy outcomes.

  • Who to Screen
  • What to Include in the Screening Panel
  • What is High or Low Risk Thrombophilia?
  • Anticoagulation for VTE Prophylaxis
  • VTE in Pregnancy – The Basics
  • Clinically Relevant Thrombophilias
  • Adverse Pregnancy Outcomes
  • Anticoagulation Medications in Pregnancy
  • Definitions – Anticoagulation Regimens (ACOG)

Who to Screen  

Consider screening for inherited thrombophilias in the following scenarios 

  • A personal history of VTE 
    • With or without a recurrent risk factor 
      • Recurrent risk factor examples: Pregnancy or OCP use 
      • Non-recurrent risk factor examples: Surgery or immobilization  
  • Family history 
    • First-degree relative with a history of high-risk inherited thrombophilia 

Screening is not recommended for the following 

  • Personal history of  
    • Fetal loss  
    • Abruption 
    • Preeclampsia 
    • Fetal growth restriction

Note: Consider testing for acquired antiphospholipid syndrome antibodies in women with recurrent pregnancy loss or stillbirth

What to Include in the Screening Panel

  • Factor V Leiden pathogenic variant  
  • Prothrombin G20210A pathogenic variant  
  • Antithrombin deficiency (activity <60%) 
  • Protein S deficiency (functional assay <55%)  
  • Protein C deficiency (activity <65%)  
  • Antiphospholipid antibodies (acquired thrombophilia)

Note: If possible, screen 

  • >6 weeks from VTE  
  • Nonpregnant  
  • Not on anticoagulation or hormonal therapy

What is High or Low Risk Thrombophilia?

High Risk Thrombophilia

  • Antithrombin deficiency
  • Antiphospholipid syndrome (APS)
  • Factor V Leiden or Prothrombin pathogenic variants
    • Homozygosity or compound heterozygosity

Low Risk Thrombophilia

  • Factor V Leiden or Prothrombin pathogenic variant
    • Heterozygote state
    • Protein C or S deficiency

Anticoagulation for VTE Prophylaxis

Low-risk thrombophilia without personal VTE history 

  • Antepartum
    • Surveillance without anticoagulation therapy 
  • Postpartum
    • Surveillance without anticoagulation therapy or 
    • Postpartum prophylactic anticoagulation therapy if additional risk factors (e.g., obesity, immobilization, cesarean section)  

Low-risk thrombophilia plus first-degree relative VTE history 

  • Antepartum
    • Surveillance without anticoagulation therapy or 
    • Prophylactic LMWH/UFH  
  • Postpartum
    • Postpartum prophylactic anticoagulation therapy or 
    • Intermediate-dose LMWH/UFH  

Low-risk thrombophilia with single episode of VTE (not receiving long-term anticoagulation therapy)  

  • Antepartum
    • Prophylactic or intermediate-dose LMWH/UFH 
  • Postpartum
    • Postpartum prophylactic anticoagulation therapy or
    • Intermediate-dose LMWH/UFH 

High-risk thrombophilia without previous VTE

  • Antepartum:
    • Prophylactic or intermediate-dose LMWH/UFH 
  • Postpartum
    • Postpartum prophylactic anticoagulation therapy or
    • Intermediate-dose LMWH/UFH 

High-risk thrombophilia with one previous episode of VTE or affected first-degree relative (not receiving long-term anticoagulation therapy) 

  • Antepartum
    • Prophylactic or
    • Intermediate-dose LMWH/UFH or
    • Adjusted-dose LMWH/UFH  
  • Postpartum
    • Postpartum prophylactic anticoagulation therapy or
    • Intermediate-dose LMWH/UFH or
    • Adjusted-dose LMWH/UFH for 6 weeks (therapy level should equal selected antepartum treatment)  

Thrombophilia with ≥2 VTE episodes (not receiving long-term anticoagulation therapy) 

  • Antepartum
    • Intermediate-dose LMWH/UFH or
    • Adjusted-dose LMWH/UFH 
  • Postpartum
    • Intermediate-dose LMWH/UFH or
    • Adjusted-dose LMWH/UFH for 6 weeks (therapy level should equal selected antepartum treatment) 

Thrombophilia with ≥2 VTE episodes (receiving long-term anticoagulation therapy) 

  • Antepartum
    • Adjusted-dose LMWH/UFH 
  • Postpartum
    • Resumption of long-term anticoagulation therapy  
      • Oral route may be considered, depending on therapy duration, breastfeeding and patient preference

KEY POINTS:  

VTE in Pregnancy – The Basics 

  • Maternal VTE covers two potentially life-threatening events during the antepartum and postpartum periods   
    • 80% – Deep vein thrombosis (DVT)   
    • 20% – Pulmonary embolism (PE)   
  • VTE affects approximately 1 to 4 /1000 pregnancies   
  • There is a greater than 5-fold risk of VTE during pregnancy   
  • Antepartum: Highest risk in 1st and 3rd trimesters  
  • Postpartum: Highest risk in first 6 weeks   
  • Virchow’s triad is exacerbated by pregnancy    
    • Hypercoagulability  
    • Stasis  
    • Endothelial vascular damage  
  • Leading cause of maternal morbidity and mortality    
    • 15% of maternal deaths in the developed world are related to PE (WHO data)  
    • Data indicates high percentage of deaths may have been preventable

Clinically Relevant Thrombophilias 

Factor V Leiden  

  • Prevalence dependent on ethnicity/race  
    • Caucasians: 5.27% 
    • Hispanic Americans: 2.21% 
    • African Americans: 1.23% 
    • Asian Americans: 0.45% 
    • Native Americans: 1.25% 
  • Heterozygote state: VTE risk in pregnancy  
    • Without a personal history of VTE or an affected first-degree relative <age 50: Slight increased risk (5-12/1,000 deliveries)  
    • Affected first-degree relative but no personal history of VTE: Slight increased risk (15/1,000 deliveries)  
    • Personal history of VTE: 10% risk 
  • Homozygosity: VTE risk in pregnancy  
    • Without a personal history of VTE or an affected first-degree relative <age 50: 1–2% risk 
    • Personal history of VTE or an affected first-degree relative <age 50: 17% risk

Prothrombin G20210A 

  • Prevalence dependent on race/ethnicity  
    • Caucasians: 3.6% 
    • Hispanic Americans: 3.5% 
    • African Americans: 0-1.7% 
    • Asian Americans: 0.0% 
    • Native Americans: 0-0.6% 
  • Heterozygote state: VTE risk in pregnancy 
    • Without personal history of VTE: <1% risk 
    • Affected first-degree relative but no personal history of VTE: Slight increased risk 
    • Personal history of VTE: 10% risk  
  • Homozygosity: VTE risk in pregnancy  
    • Without personal or family history: 2–3% risk of VTE 

Note: Compound heterozygosity: Factor V Leiden and Prothrombin pathogenic variant: 4-5% risk (even without family or personal history)


Protein C Deficiency 

  • Multiple variants and clinical presentations  
    • Hematology consult may be helpful if patient has an abnormal protein C result 
  • VTE risk in pregnancy with protein C deficiency 
    • Personal or family history: 2-8% risk  
    • No family history: 0.7 %  
    • Family history of VTE: 1.7%  
  • Neonatal purpura fulminans (rare) 
    • Newborns who are homozygous for protein C deficiency  
    • DIC and hemorrhagic skin necrosis  
    • May also occur with Protein S deficiency

Protein S Deficiency 

  • Caused by either 
    • Silenced gene or  
    • Pathogenic variant, reducing protein S antigen levels  
  • Prevalence unknown 
  • Testing in pregnancy may be unreliable  
    • If necessary, screening in nonpregnancy advised if possible  
  • Family or personal history: 5–7% risk

Antithrombin Deficiency 

  • Rare (1/2500 heterozygote state), but confers high risk for VTE
  • Multiple pathogenic variants are known to reduce antigen level and/or activity  
  • Antithrombin deficiency is considered a high-risk thrombophilia

Methylenetetrahydrofolate Reductase Variants 

  • ACOG states “There is insufficient evidence to support assessment of methylenetetrahydrofolate reductase (MTHFR) polymorphisms or measurement of fasting homocysteine levels in the evaluation of a thrombophilic etiology for VTE.” (see ‘Related ObG Topic’, below)

Adverse Pregnancy Outcomes 

  • Larger prospective studies (NICHD / MFMU network) do not support the association between inherited thrombophilias and adverse pregnancy outcomes including  
    • Preeclampsia 
    • Fetal loss 
    • Fetal Growth Restriction 
    • Placental Abruption 
  • ACOG states “There is insufficient evidence to recommend anticoagulation as an intervention to prevent adverse pregnancy outcomes among women with inherited thrombophilias” 

Anticoagulation Medications in Pregnancy  

  • LMWH (preferred therapy) and unfractionated heparin do not cross the placenta  
  • Avoid oral direct thrombin inhibitors (dabigatran) and anti-Xa inhibitors (rivaroxaban, apixaban)
    • Insufficient safety data during pregnancy and lactation
  • To provide neuraxial anesthesia (e.g., epidural) option prior to induction of labor 
    • Adjusted-dose low-molecular-weight heparin: Hold for 24 hours prior to induction 
    • Prophylactic LMWH: Hold for 12 hours prior to induction  
    • Alternative option: Substitute unfractionated heparin close to delivery  
      • SOAP recommendations for intermediate-dose unfractionated heparin (eg, 7500 U SQ twice daily or 10,000 U SQ twice daily): Consider holding the dose 12 hours and assessing coagulation status before placing a neuraxial anesthetic  (link to SOAP Consensus Statement in the ‘Learn More – Primary Sources’ section below)  
  • Patients receiving anticoagulation 
    • Hold injections with onset of labor 
    • Rapid reversal: Protamine sulfate, with dosing dependent on medication and route

Note: Consider sequential compression devices (SCDs)  

  • Intrapartum
    • Indicated in patients with known thrombophilia until fully ambulatory postpartum  
  • Cesarean section
    • All women undergoing cesarean delivery
    • Add pharmacologic prophylaxis depending on clinical scenario (see guidelines, above)

Definitions – Anticoagulation Regimens (ACOG)  

LMWH – Prophylactic

  • Enoxaparin, 40 mg SC once daily
  • Dalteparin, 5,000 units SC once daily
  • Tinzaparin, 4,500 units SC once daily
  • Nadroparin, 2,850 units SC once daily

LMWH-Intermediate Dose

  • Enoxaparin, 40 mg SC every 12 hours
  • Dalteparin, 5,000 units SC every 12 hours

LMWH – Adjusted Dose (Therapeutic)    

  • Enoxaparin, 1mg/kg SC every 12 hours
  • Dalteparin, 200 units/kg SC once daily
  • Tinzaparin, 175 units/kg SC once daily
  • Dalteparin, 100 units/kg every 12 hours 

Note: anti-Xa level 

  • 0.6-1.0 units/mL 4 hr after last injection for q12 hr regimen
  • Slightly higher doses for daily regimen

UFH – Prophylactic 

  • UFH, 5,000-7,500 units SC every 12 hours in first trimester  
  • UFH, 7,500-10,000 units SC every 12 hours in the second trimester  
  • UFH, 10,000 units SC every 12 hours in the third trimester, unless the aPTT is elevated   

UFH – Adjusted Dose (Therapeutic)

  • UFH, 10,000 units or more SC every 12 hours in doses adjusted to target aPTT in the therapeutic range (1.5-2.5x) 6 hours after the injection     

Postpartum Anticoagulation 

  • Prophylactic, intermediate or adjusted dose LMWH for 6-8 weeks as indicated
  • Oral anticoagulants may be considered postpartum based upon planned duration of therapy, lactation and patient preference 

Surveillance    

  • Clinical vigilance and appropriate objective investigation of women with symptoms suspicious of deep vein thrombosis or pulmonary embolism
  • Perform VTE risk assessment prepregnancy or early in pregnancy and repeat if complications develop 

Learn More – Primary Sources:

ACOG Practice Bulletin 197: Inherited Thrombophilias in Pregnancy

The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the Anesthetic Management of Pregnant and Postpartum Women Receiving Thromboprophylaxis or Higher Dose Anticoagulants

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications Direct to Your Phone

ObGFirst® – Try It Free! >>

image_pdfFavoriteLoadingFavorite

< Previous
All Alerts Posts
Next >

Related ObG Topics:

The CMQCC Toolkit: Pregnancy Related Risk Factors & Thrombophilia Defined
The CMQCC Toolkit: Venous Thromboembolism in Early Pregnancy
The CMQCC Toolkit: Venous Thromboembolism Prevention and Management at Delivery
The CMQCC Toolkit: Venous Thromboembolism and Antepartum Admission (Non-Delivery)
MTHFR Polymorphism Testing – The Evidence Isn’t There
Which Thrombophilias in Pregnancy Warrant Thromboprophylaxis? 

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site